Press Release
TransEnterix Announces Japanese Regulatory Approval of the Senhance Surgical System
“Regulatory approval in
The Senhance Surgical System was approved (“Shonin”) by the
"Approval of the Senhance Surgical System for use in laparoscopic
procedures in
About
About
Forward-Looking Statements
This press release includes statements relating to the current
regulatory and commercialization plans for the Senhance Surgical System.
These statements and other statements regarding our future plans and
goals constitute "forward looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and are intended to qualify for the
safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks and
uncertainties that are often difficult to predict, are beyond our
control and which may cause results to differ materially from
expectations and include whether the Japanese robotic surgical market
will create a considerable market opportunity for the Senhance Surgical
System and whether the Senhance Surgical System will allow surgeons to
offer excellent minimally invasive procedures that add precision and
visual control while leveraging a familiar laparoscopic approach with
minimal additional costs to the health system. For a discussion of the
risks and uncertainties associated with
View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005181/en/
Source:
For TransEnterix, Inc.
Investors:
Mark Klausner, +1
443-213-0501
invest@transenterix.com
or
Media:
Joanna
Rice, +1 951-751-1858
joanna@greymattermarketing.com